仿制药冲击加剧诺华制药(NVS.US)预警2026年利润将下滑

智通财经02-04

智通财经APP获悉，2月4日美股盘前，诺华制药(NVS.US)公布2025年第四季度业绩。财报显示，诺华制药四季度营收为 133.4 亿美元，同比增长 1.4%，较预期低 7.4 亿美元；非GAAP每股收益为2.03美元，超出预期0.03美元。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物（如心脏病治疗药物Entresto）将进一步受到仿制药竞争冲击。该公司周三表示，按固定汇率计算，其...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608013353?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-04 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608013353","market":"hk","top_or_hot":-1,"title":"仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，2月4日美股盘前，诺华制药(NVS.US)公布2025年第四季度业绩。财报显示，诺华制药四季度营收为 133.4 亿美元，同比增长 1.4%，较预期低 7.4 亿美元；非GAAP每股收益为2.03美元，超出预期0.03美元。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物（如心脏病治疗药物Entresto）将进一步受到仿制药竞争冲击。该公司周三表示，按固定汇率计算，其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401510.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-04 15:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401510.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，2月4日美股盘前，诺华制药(NVS.US)公布2025年第四季度业绩。财报显示，诺华制药四季度营收为 133.4 亿美元，同比增长 1.4%，较预期低 7.4 亿美元；非GAAP每股收益为2.03美元，超出预期0.03美元。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物（如心脏病治疗药物Entresto）将进一步受到仿制药竞争冲击。该公司周三表示，按固定汇率计算，其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401510.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401510.html","article_id":"2608013353","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608013353","pubTimestamp":1770191316,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，2月4日美股盘前，诺华制药公布2025年第四季度业绩。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物将进一步受到仿制药竞争冲击。随着Entresto及其他老牌畅销药受到仿制药竞争者冲击，首席执行官Vas Narasimhan专注于创新药物的战略今年将面临考验。诺华已承诺在美国新建七处生产设施，这是其斥资230亿美元扩大该国制造规模计划的一部分。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4007":"制药","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK1191":"制药","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","NVS":"诺华","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK1574":"生物医药B类股","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","01477":"欧康维视生物-B","BK4578":"CAR-T","BK4588":"碎股"},"translate_title":"Generic drug impact intensifies Novartis Pharmaceuticals (NVS.US) warns of profit decline in 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1.5,"01477":1.5},"content_text":"智通财经APP获悉，2月4日美股盘前，诺华制药(NVS.US)公布2025年第四季度业绩。财报显示，诺华制药四季度营收为 133.4 亿美元，同比增长 1.4%，较预期低 7.4 亿美元；非GAAP每股收益为2.03美元，超出预期0.03美元。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物（如心脏病治疗药物Entresto）将进一步受到仿制药竞争冲击。该公司周三表示，按固定汇率计算，其核心营业利润可能下降低个位数百分比。销售额预计将实现低个位数增长。随着Entresto及其他老牌畅销药受到仿制药竞争者冲击，首席执行官Vas Narasimhan专注于创新药物的战略今年将面临考验。诺华正推出一款治疗自身免疫性皮肤病的新药丸，并即将公布针对心脏病和多发性硬化症等疾病的实验性疗法关键数据。为促进增长，Vas Narasimhan也在积极达成交易。去年九月，诺华同意收购美国生物科技公司Tourmaline Bio，以获得一种前景广阔、可降低全身性炎症(心血管疾病主要诱因)的疗法。随后的十月，该公司达成了十多年来最大规模的收购协议，同意以高达120亿美元的价格收购Avidity Biosciences，后者已开发出数种潜在重磅药物。诺华近期解决了其在美国(全球最大医药市场)业务未来发展的部分不确定性。与本土竞争对手罗氏控股类似，这家瑞士公司在圣诞节前与特朗普政府达成协议，通过承诺降价换取免受行业关税等新规影响的保护。诺华已承诺在美国新建七处生产设施，这是其斥资230亿美元扩大该国制造规模计划的一部分。其中大部分投资将集中于放射性配体疗法。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608013353","isCrawlerRequest":true}

仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑

精彩评论

仿制药冲击加剧诺华制药(NVS.US)预警2026年利润将下滑